Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
about
Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseasesCombinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infectionCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations.Long-acting slow effective release antiretroviral therapy.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityPreclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyMacrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsLong-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugsDevelopment and characterization of a long-acting nanoformulated abacavir prodrugSmall magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Creation of a long-acting nanoformulated dolutegravir.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.
P2860
Q21133553-1EB49C38-7596-4ED5-B7BD-91C26862CFFAQ28394163-47E4AA9C-960B-4E63-848B-80C1402703FAQ28551873-A9AA92FC-2F7B-4626-A213-BD9944DDB8B0Q30603781-548ED2BE-D39F-4A71-A043-0CE9427DE698Q33625213-59476594-CBAA-4F39-B7D3-77C34FA4725EQ34512904-9C77079E-B659-475B-8B6C-EDC56BA52453Q34745586-30D91AA6-CC88-4044-9CF6-A7DA9DB3FEFFQ35153311-7EB973FE-4804-4917-AB45-B8B521FEC976Q35979166-1F6495BC-4B38-416A-A610-92EA6CD20F16Q36020685-FFDEAD62-0FD4-46C7-ACFD-808D3D38CBD1Q36262152-5D67A091-508F-49B6-84DC-971979420248Q36603756-6AE4EF8A-FC31-4248-8E48-8A4E2DF54E29Q36875347-1BF39C45-AAB5-47F2-85D8-A48ECF441A81Q36969787-F58E3025-E1BC-4887-863B-481EB4BE8A98Q37188867-5DE96B53-C130-4E90-A150-BA68898A5D46Q37704651-B563D596-D6F0-4BD9-806B-14C8519CC4BAQ38992323-36A5254D-E780-4CDC-98AA-5661AFC4D514Q41280373-BEF2677F-B114-4A58-812D-1B7FC247A5F9Q41905223-E0B87A59-FF3C-4E90-AADD-EB0D8A0617ADQ47603651-2E9695B8-30CF-452A-AA6F-6C559EF14BEEQ50051618-1011C9DA-EA4E-4D5D-9D5E-5755E3BBF9B1Q54267469-A7332E24-029D-403D-81C8-1BC47C8A8295
P2860
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
@ast
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
@en
type
label
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
@ast
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
@en
prefLabel
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
@ast
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
@en
P2093
P2860
P356
P1476
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
@en
P2093
Alexander V Kabanov
Andrea Martinez-Skinner
Ari S Nowacek
Georgette Kanmogne
Howard E Gendelman
JoEllyn McMillan
R Lee Mosley
Ram S Veerubhotla
Shantanu Balkundi
P2860
P304
P356
10.2147/IJN.S27830
P407
P50
P577
2011-12-20T00:00:00Z